Last Updated: 13 Sep 2024
Executive Summary
Edwards Lifesciences Corp (EW) is a leading medical technology company specializing in artificial heart valves and hemodynamic monitoring. With a market capitalization of $41.04 billion, the company has been delivering strong financial performance, including a 20.6% increase in quarterly earnings growth year-over-year. Analysts are bullish on the stock, with 6 strong buy ratings and 14 buy ratings. The stock's current price of $68.13 is below the analyst target price of $78.82.
Company Overview
Edwards Lifesciences is headquartered in Irvine, California and operates globally. The company's products are used in the treatment of cardiovascular diseases, including heart valve disease, aortic stenosis, and mitral regurgitation. Edwards Lifesciences has a strong research and development pipeline, with a focus on innovative technologies such as transcatheter heart valves and hemodynamic monitoring systems.
Fundamental Analysis
Edwards Lifesciences has a solid financial foundation. The company's revenue for the trailing twelve months (TTM) was $6.20 billion, with a gross profit margin of 69.3%. The company's operating margin TTM is 27.2%, and its return on assets TTM is 12.3%. Edwards Lifesciences has a strong balance sheet, with $1.72 billion in cash and equivalents and total debt of $1.40 billion.
Technical Analysis
Technically, Edwards Lifesciences stock is in a bullish trend. The stock's 50-day moving average is $73.75, and its 200-day moving average is $81.42. The stock is currently trading below both moving averages, but it has been making higher lows and higher highs since the start of the year.
Short Term Outlook
In the short term, Edwards Lifesciences stock is expected to continue its bullish trend. The stock is trading above its 50-day moving average, and it is approaching its 200-day moving average. The company's strong financial performance and positive analyst sentiment are likely to continue to support the stock price.
Long Term Outlook
In the long term, Edwards Lifesciences stock is expected to continue to perform well. The company's strong fundamentals, innovative product pipeline, and global reach position it for continued growth. The aging population and increasing prevalence of cardiovascular diseases are also expected to drive demand for the company's products.
Analyst Recommendations
Analysts are bullish on Edwards Lifesciences stock. The consensus analyst rating is buy, with a target price of $78.82. Six analysts have a strong buy rating on the stock, 14 have a buy rating, 10 have a hold rating, and two have a sell rating.
